Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?

Expert Opinion on Emerging Drugs

Volumn 18, Issue 1, 2013, Pages 5-7

  Wendling, Daniel ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Ankylosing spondylitis; Anti TNF agents; IL 17; IL 23; Spondyloarthritis; Treatment

Indexed keywords

ABATACEPT; ALENDRONIC ACID; CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; USTEKINUMAB;

ADD ON THERAPY; ANKYLOSING SPONDYLITIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874609252     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2013.749857     Document Type: Review

References (94)

1. Wendling D, Toussirot E. Anti-TNF-alpha therapy in ankylosing spondylitis. Expert Opin Pharmacother 2004;5(7):1497-507
2. McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11(28):1-158
3. Emery P, Busquets-Perez N, Marzo-Ortega H. Emerging drugs for ankylosing spondylitis. Expert Opin Emerg Drugs 2013;18(1):71-86
4. Pham T, Bachelez H, Berthelot JM, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78(Suppl 1):15-185
5. Wendling D, Prati C. Biologic agents for treating ankylosing spondylitis: beyond TNFa antagonists. Joint Bone Spine 2011;78(6):542-4
6. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD004524
7. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD004800
8. van Denderen JC, van der Paardt M, Nurmohamed MT, et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005;64(12):1761-4 (Pubitemid 41667152)
9. Mulleman D, Lauferon F, Wendling D, et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011;13(3):R82
10. Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10
11. Lekpa FK, Farrenq V, Canou?-Poitrine F, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012;79:47-50
12. Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7
13. Wendling D, Dougados M, Berenbaum F, et al. Rituximab Treatment for Spondyloarthritis. A Nationwide Series: data from the AIR Registry of the French Society of Rheumatology. J Rheumatol 2012; [Epub ahead of print]
14. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64(2):296-8 (Pubitemid 40193630)
15. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63(9):1041-5 (Pubitemid 39120352)
16. Wendling D. Interleukin-6 as a therapeutic target in spondylarthritis: comment on the article by Tanaka et al. Arthritis Care Res (Hoboken) 2010;62(5):745
17. Lekpa FK, Poulain C, Wendling D, et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther 2012;14(2):R53
18. Sieper J, Porter-Brown B, Thompson L, et al. Tocilizumab (tcz) is not effective for the treatment of ankylosing spondylitis (as): results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial [op0166]. Ann Rheum Dis 2012;71(Suppl 3):110
19. Sieper J, Inman RD, Badalamenti S, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align) [op0169]. Ann Rheum Dis 2012;71(Suppl 3):111
20. Wendling D. IL-23 and IL-17 in ankylosing spondylitis. Rheumatol Int 2010;30(11):1547
21. Baeten D, Sieper J, Emery P, et al. The anti-IL17A monoclonal antibody Secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010;62:3840-1
22. Available from: http://clinicaltrials.gov/ct2/show/NCT01330901
23. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71(10):1616-22
24. Haroon N, Kim TH, Inman RD. NSAIDs and radiographic progression in ankylosing spondylitis Bagging big game with small arms? Ann Rheum Dis 2012;71(10):1593-5
25. Braem K, Lories RJ. Insights into the pathophysiology of ankylosing spondylitis: contributions from animal models. Joint Bone Spine 2012;79(3):243-8
26. Carter S, Braem K, Lories RJ. The role of bone morphogenetic proteins in ankylosing spondylitis. Ther Adv Musculoskelet Dis 2012;4(4):293-9
27. Braun J, Sieper J, Zink A. The risks of smoking in patients with spondyloarthritides. Ann Rheum Dis 2012;71(6):791-2
28. Wendling D, Prati C, Goupille P, Mulleman D. Optimizing TNFa antagonist therapy in patients with spondyloarthritis: why and how? Joint Bone Spine 2011;78(3):225-7
29. Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011;77(10):1005-12
30. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008;12(4):540-6
31. Pugliatti M, Beghi E, Forsgren L, et al. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48(12):2224-33 (Pubitemid 350243405)
32. Mula M. New antiepileptic drugs: molecular targets. Cent Nerv Syst Agents Med Chem 2009;9(2):79-86
33. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069-77
34. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010;51(1):7-26
35. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5(7):553-64 (Pubitemid 38868551)
36. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4(1):18-61 (Pubitemid 46107329)
37. Lee CY, Fu WM, Chen CC, et al. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 2008;49(5):888-97
38. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1):S10-16
39. Stafstrom CE. Persistent sodium current and its role in epilepsy. Epilepsy Curr 2007;7(1):15-22
40. Yu FH, Yarov-Yarovoy V, Gutman GA, Catterall WA. Overview of molecular relationships in the voltage-gated ion channel superfamily. Pharmacol Rev 2005;57(4):387-95 (Pubitemid 43036430)
41. Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res 2006;68(1):22-8
42. Jung HY, Mickus T, Spruston N. Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons. J Neurosci 1997;17(17):6639-46 (Pubitemid 27366616)
43. Catterall WA, Striessnig J, Snutch TP, Perez-Reyes E. International Union of Pharmacology. XL. Compendium of voltage-gated ion channels: calcium channels. Pharmacol Rev 2003;55(4):579-81 (Pubitemid 37500517)
44. Cunningham MO, Woodhall GL, Thompson SE, et al. Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. Eur J Neurosci 2004;20(6):1566-76 (Pubitemid 39294695)
45. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39(11):2139-46 (Pubitemid 30645637)
46. Rogawski MA. KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy. Trends Neurosci 2000;23(9):393-8
47. Kobayashi T, Hirai H, Iino M, et al. Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 2009;56(2):499-506
48. Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3) H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295(3):1086-93
49. Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res 2005;63(1):17-25 (Pubitemid 40220335)
50. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45(5):661-71 (Pubitemid 36980822)
51. Deeks ED. Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. CNS Drugs 2011;25(10):887-900
52. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15(5):339-50
53. Barrese V, Miceli F, Soldovieri MV, et al. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clin Pharmacol 2010;2:225-36
54. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci 2005;6(3):215-29 (Pubitemid 40342416)
55. Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol Sci 2003;24(10):542-9
56. Rogawski MA, Kurzman PS, Yamaguchi SI, Li H. Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse. Neuropharmacology 2001;40(1):28-35 (Pubitemid 33779797)
57. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11(2):56-63
58. Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005;5(1):1-6
59. Vezzani A, Bartfai T, Bianchi M, et al. Therapeutic potential of new antiinflammatory drugs. Epilepsia 2011;52(Suppl 8):67-9
60. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 2000;857(1-2):246-51 (Pubitemid 30107811)
61. Matoth I, Pinto F, Sicsic C, Brenner T. Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci Res 2000;38(2):209-12
62. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92(2-3):89-124
63. Laxer K, Blum D, Abou-Khalil BW, et al. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000;41(9):1187-94
64. Monaghan EP, Navalta LA, Shum L, et al. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997;38(9):1026-31 (Pubitemid 27382941)
65. Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res 2000;42(2-3):133-9
66. Pieribone VA, Tsai J, Soufflet C, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia 2007;48(10):1870-4 (Pubitemid 47537451)
67. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52(7):1331-40
68. French JA, Krauss GL, Biton V, et al Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study Neurology 2012; 79(6): 589-96
69. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78(18):1408-15
70. Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term openlabel evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263-9
71. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study Epilepsia 2012; Epub ahead of print
72. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III studyv. Epilepsia 2012 305 ; [Epub ahead of print]
73. Howes JF, Bell C. Talampanel. Neurotherapeutics 2007;4(1):126-9 (Pubitemid 46107320)
74. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 2007;73(1):1-52 (Pubitemid 46091734)
75. Besag FM, Patsalos PN. New developments in the treatment of partial-onset epilepsy. Neuropsychiatr Dis Treat 2012;8:455-64
76. Auberson YP. BGG492, a competitive ampa/kainate antagonist for the treatment of epilepsy. 2emes Journeees Scientifiques du Medicament; Grenoble; 2012. p. 9
77. Russo E, Gitto R, Citraro R, et al. New AMPA antagonists in epilepsy. Expert Opin Investig Drugs 2012;21(9):1371-89
78. Pitkanen A, Mathiesen C, Ronn LC, et al. Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 2007;74(1):45-54 (Pubitemid 46413707)
79. Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia 2009;50(Suppl 12):49-50
80. Gormsen L, Finnerup NB, Almqvist PM, Jensen TS. The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg 2009;108(4):1311-19
81. Maroso M, Balosso S, Ravizza T, et al. Interleukin-1beta biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 2011;8(2):304-15
82. Ravizza T, Lucas SM, Balosso S, et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia 2006;47(7):1160-8 (Pubitemid 44086751)
83. Ravizza T, Noe F, Zardoni D, et al. Interleukin converting enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production. Neurobiol Dis 2008;31(3):327-33
84. Cornelis S, Kersse K, Festjens N, et al. Inflammatory caspases: targets for novel therapies. Curr Pharm Des 2007;13(4):367-85 (Pubitemid 46477759)
85. Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2012; [Epub ahead of print]
86. French JA, Costantini C, Brodsky A, von Rosenstiel P. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519-25
87. Pharmaprojects. Pharmaprojects-copyright to Citeline Drug Intelligence (an informa business). 2012
88. Labiner DM. DP-VPA D-Pharm. Curr Opin Investig Drugs 2002;3(6):921-3
89. Dahan A, Duvdevani R, Shapiro I, et al. The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release 2008;126(1):1-9
90. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68(20):1701-9 (Pubitemid 46763258)
91. Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 2009;23(2):121-37
92. Mula M, Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009;11(1):1-9
93. Mula M. Treatment-emergent psychiatric adverse events of antiepileptic drugs in epilepsy: how can we avoid them? Neuropsychiatry 2011;1(4):371-6
94. Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem 2008;2:21-39